15,800 may be present in urine from such patients, six random urine specimens were obtained with informed consent over a 3-day period from a 29 year old, 6 ft. tall, white male outpatient weighing 200 [bs. who was being treated for AADHD with 30 rag/day of dextroamphetamine. The subject was in good health, drank coffee, and smoked one pack of cigarettes daily. For two months preceding and at the time of the specimen collection, the patient was ingesting 10-rag Dexedrine | sustained-release capsules twice daily (two in the morning and one after lunch). Amphetamine quantitation was performed by liquid-liquid extraction and HFBA derivatization followed by GC-MS analysis as previously described (4) . The results of these analyses are presented in Table I . In five of the six specimens, amphetamine urine concentration far exceeded those determined in my laboratory as part of a controlled study following single 20-rag doses (5) . In that study, the highest dextroamphetamine urine concentration observed in all the urines collected from seven subjects was 4,500 ng/mL. However, it should be noted that the AADHA subject in this present report was at pharmacokinetic "steady-state" for two months. The range of concentrations in Table ] (1100-17,800 ng/mL) should caution toxicologists against making assumptions as to ingested drug dose based upon the results of a single random urine drug test.
Forensic toxicologists, particularly those involved with regulated and nonregulated pre-employment and employee urine drug testing, should be aware of the recent medical indication of dextroamphetamine pharmacotherapy for AADHA.
